Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Start price
02.08.24
/
50%
€992.60
Target price
02.08.25
€1,099.3
Performance (%)
-0.16%
Price
02.08.24
€991.00
Summary
This prediction is currently active. Since the start of the prediction for Regeneron Pharmaceuticals Inc. the price has only changed by -0.16%. This prediction currently runs until 02.08.25. The prediction end date can be changed by Wells_Fargo___Compan at any time. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | -0.16% |
| iShares Core DAX® | -3.935% |
| iShares Nasdaq 100 | -3.608% |
| iShares Nikkei 225® | -4.513% |
| iShares S&P 500 | -2.607% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Wells Fargo & Company from $1,125.00 to $1,200.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat